Craft
  • Home
  •  / Kite Pharma
Kite Pharma

Kite Pharma

Revenue

$22.2 M

FY, 2016

Kite Pharma Summary

Company summary

Overview
Kite Pharma is a development-stage biotechnology company designing and developing immune-based therapies to treat cancer indications. The Company is developing a pipeline of engineered autologous cell therapy-based product candidates for the treatment of solid and hematological malignancies. Its lead product candidate is KTE-C19, a chimeric antigen receptor (CAR)-based therapy that is in Phase 2 clinical trials for patients with relapsed or refractory aggressive diffuse large B cell lymphoma, primary mediastinal B cell lymphoma, and transformed follicular lymphoma.
Type
Subsidiary
Founded
2009
HQ
Santa Monica, CA, US | view all locations
Website
http://www.kitepharma.com
Cybersecurity rating
Sectors

Key people

  • Christi Shaw

    Christi Shaw, Chief Executive Officer

    • Brad Glover

      Brad Glover, VP & Head of Strategy

    • Adrian Bot

      Adrian Bot, VP of Scientific Affairs

    LocationsView all

    9 locations detected

    • Santa Monica, CA HQ

      United States

      2400 Broadway

    • El Segundo, CA

      United States

      2355 Utah Ave

    • Emeryville, CA

      United States

      5858 Horton St #240

    • Frederick, MD

      United States

      Bennett Creek Blvd

    • Oceanside, CA

      United States

      4010 Ocean Ranch Blvd

    • Amsterdam, Noord-Holland

      Netherlands

      408 Science Park

    and 3 others

    Kite Pharma Financials

    Summary financials

    Revenue (Q2, 2017)
    $10.1M
    Net income (Q2, 2017)
    ($109.8M)
    Cash (Q2, 2017)
    $147.8M
    EBIT (Q2, 2017)
    ($101.9M)

    Footer menu